Vol. 291, Issue 3, 1093-1099, December 1999

Ring-Constrained Orvinols as Analogs of Buprenorphine: Differences in Opioid Activity Related to Configuration of C₂₀ Hydroxyl Group¹

J. R. Traynor , L. Guo, A. Coop² , J. W. Lewis and J. H. Woods

Department of Chemistry, University of Bristol, UK (A.C., J.W.L.); Department of Chemistry, Loughborough University, UK (J.R.T., L.G.); and Departments of Pharmacology (J.R.T., J.H.W.) and Psychology (J.H.W.), University of Michigan Medical School, Ann Arbor, Michigan

The relative positions of the C₂₀ substituents in buprenorphine, particularly the hydroxyl group, have been implicated in its actions as a partial µ-agonist and a -antagonist. This hypothesis has been examined by the synthesis and pharmacological characterization of five orvinols in which the C₂₀ carbon atom of buprenorphine is constrained in a five-membered ring, fixing the hydroxyl group above () or below () the plane of the ring. All five compounds were nonselective in binding assays with similar, low nanomolar affinities. The compounds acted as -agonists in the mouse vas deferens and -agonists in the myenteric plexus-longitudinal muscle of the guinea pig ileum and in Chinese hamster ovary (CHO) cells expressing the human -opioid receptor (CHO-hkor). All were lower efficacy µ-agonists than buprenorphine as measured by the [³⁵S]guanosine-5'-O-(3-thio)triphosphate assay in SH-SY5Y cells. The major difference between the isomers was an 11- to 12-fold higher potency of the -OH isomer (BU46) compared with the -OH isomer (BU47) at the -receptor in the guinea pig ileum and CHO-hkor cells and a somewhat higher efficacy of BU46 in CHO-hkor cells. BU46 and BU47 were evaluated in vivo. BU46 was a full agonist in the mouse writhing assay and antinociception was prevented by norbinaltorphimine, showing a -mechanism of action. In contrast, BU47 acted as an antagonist of µ-, -, and -mediated antinociception in the writhing assay. The results show that the configuration of the hydroxyl group is not important in binding affinity at µ-, -, or -receptors but does influence -potency and -efficacy, particularly in vivo.